MALIGNANT PLEURAL MESOTHELIOMA
Clinical trials for MALIGNANT PLEURAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PLEURAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for MALIGNANT PLEURAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug cocktail targets Hard-to-Treat mesothelioma
Disease control OngoingThis phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: Hyogo Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immunotherapy before surgery shows promise for mesothelioma patients
Disease control OngoingThis study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) before surgery is safe and feasible for people with resectable malignant pleural mesothelioma. About 30 adults with epithelial or biphasic mesothelioma will receive the drugs, then undergo …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New radiation method aims to reduce lung damage in mesothelioma patients
Disease control OngoingThis study tests a new radiation technique called IMRT for people with malignant pleural mesothelioma, a rare lung cancer. The goal is to see if combining surgery, chemotherapy, and this targeted radiation is safe and reduces severe lung side effects. About 65 adults with early-s…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy for mesothelioma shows early promise
Disease control OngoingThis early-phase trial is testing whether combining the immunotherapy drug pembrolizumab with a precise type of radiation (IMPRINT) is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. The study involves 7 participants whose cancer cannot be r…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New radiation approach shows promise for mesothelioma patients
Disease control OngoingThis study tests a new way to give radiation therapy to people with malignant pleural mesothelioma, a rare and serious lung cancer. The treatment uses a special machine called Tomotherapy to deliver high doses of radiation over just 5 days. The goal is to see if this short, inten…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered t cells take on chest cancer in new trial
Disease control OngoingThis study tests a treatment using a patient's own immune cells (T cells) that are genetically modified to recognize and attack a protein called mesothelin found on cancer cells. The treatment is given through a tube in the chest to people with malignant pleural disease, includin…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug cocktail aims to shrink mesothelioma before surgery
Disease control OngoingThis early study tests whether giving nivolumab (an immunotherapy) along with standard chemotherapy before surgery is safe and feasible for people with malignant pleural mesothelioma. The main goal is to see if this approach delays surgery by more than 30 days. 22 participants wi…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 16:52 UTC
-
Blood test may predict immunotherapy success in lung and kidney cancers
Knowledge-focused OngoingThis study is looking at whether changes in a blood test called tumor fraction can help predict how well immunotherapy works in people with non-small cell lung cancer or kidney cancer. About 100 adults will have blood samples taken before and during their standard treatment. The …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC